Browsing Tag
ASX
164 posts
ASX: CTP, ECH and CUE ink multi-year gas contract with NT govt, Palm Valley wells to drill mid-2026
Central Petroleum (ASX: CTP), Echelon Resources and Cue Energy sign binding NT Government gas deal covering 21 PJ through 2034. Two new Palm Valley wells to boost output 40%. Read more.
PainChek just unlocked US Medicare reimbursement. Here’s what the ASX: PCK bull case looks like now
PainChek (ASX: PCK) has FDA clearance and a 30,000-bed US pipeline. Here's what the RTM reimbursement pathway means for retail investors watching PCK.
Beetaloo Energy Australia raises fresh capital as ASX:BTL moves closer to first pilot gas sales
Beetaloo Energy Australia has raised A$66.3m and expanded its Macquarie facility. Read how ASX:BTL is positioning for first pilot gas in Q4 2026.
Santos (ASX: STO) confirms Quokka-1 appraisal success on Alaska’s North Slope as Pikka phase 1 nears first oil
Santos confirms Quokka-1 appraisal success on Alaska's North Slope as Pikka phase 1 nears first oil. What it means for STO investors and the Nanushuk play. Read more.
XGL (ASX): Can Xamble Group’s influencer and loyalty pivot unlock value for retail investors?
Xamble Group (ASX: XGL) trades below A$0.02 with a A$4m market cap. Here's what retail investors need to know about its live commerce, loyalty and creator strategy in 2026.
DPM Metals (DPM) Q1 2026 production on track as Vareš ramp-up proceeds and Serbia drilling accelerates
DPM Metals reports 84,000 GEO in Q1 2026 as Vareš ramps up and Čoka Rakita drilling accelerates. Full analysis of production, margins and what comes next. Read more.
Multistack International (ASX: MSI) to sell operating assets to Hong Kong buyer and pursue new business pathway
Multistack International Limited plans to sell its operating business and seek a new activity. Read what the ASX: MSI reset could mean now.
Archer Materials (AXE) advances Biochip to beta prototype as silicon-first strategy targets clinical validation
Archer Materials (ASX: AXE) advances its Biochip medical diagnostic to beta prototype, targeting clinical trials via silicon-first strategy and Stage 2 imec partnership. Read the full analysis.
Algorae Pharmaceuticals (ASX: 1AI) raises A$4m to fund dual commercial and AI drug discovery growth strategy
Algorae Pharmaceuticals (ASX: 1AI) raises A$3.99m to scale AlgoraeRx commercial portfolio and advance AlgoraeOS AI drug pipeline. Read the full strategic analysis.
IsoEnergy extends Toro Energy acquisition deadline to June 2026 and provides A$2m bridging loan as scheme nears critical vote
IsoEnergy extends Toro Energy scheme deadline to June 2026 and advances a A$2 million bridging loan. Read our full analysis of what this means for uranium investors.